These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1558 related articles for article (PubMed ID: 26545340)

  • 21. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.
    Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S
    Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease.
    Vella LJ; Hill AF; Cheng L
    Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease.
    Ganguly G; Chakrabarti S; Chatterjee U; Saso L
    Drug Des Devel Ther; 2017; 11():797-810. PubMed ID: 28352155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats.
    Lu LN; Qian ZM; Wu KC; Yung WH; Ke Y
    Mol Neurobiol; 2017 Sep; 54(7):5213-5224. PubMed ID: 27578012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.
    Peters DG; Connor JR; Meadowcroft MD
    Neurobiol Dis; 2015 Sep; 81():49-65. PubMed ID: 26303889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review.
    Gsell W; Strein I; Krause U; Riederer P
    J Neural Transm Suppl; 1997; 51():145-59. PubMed ID: 9470135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease.
    Van Bulck M; Sierra-Magro A; Alarcon-Gil J; Perez-Castillo A; Morales-Garcia JA
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30743990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
    Jenner P
    Pathol Biol (Paris); 1996 Jan; 44(1):57-64. PubMed ID: 8734302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial iron metabolism and neurodegenerative diseases.
    Cheng R; Dhorajia VV; Kim J; Kim Y
    Neurotoxicology; 2022 Jan; 88():88-101. PubMed ID: 34748789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
    Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
    J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological metals and metal-targeting compounds in major neurodegenerative diseases.
    Barnham KJ; Bush AI
    Chem Soc Rev; 2014 Oct; 43(19):6727-49. PubMed ID: 25099276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel drug delivery systems for releasing growth factors to the CNS: focus on Alzheimer's and Parkinson's diseases.
    Herran E; Igartua M; Pedraz JL; Hernandez RM
    Mini Rev Med Chem; 2014; 14(7):557-66. PubMed ID: 24958218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ironing out the Brain.
    Ward RJ; Crichton RR
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of iron in neurotoxicity: a cause for concern in the elderly?
    Stankiewicz JM; Brass SD
    Curr Opin Clin Nutr Metab Care; 2009 Jan; 12(1):22-9. PubMed ID: 19057183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.
    Majd S; Power JH; Grantham HJ
    BMC Neurosci; 2015 Oct; 16():69. PubMed ID: 26499115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System.
    Joppe K; Roser AE; Maass F; Lingor P
    Front Neurosci; 2019; 13():15. PubMed ID: 30723395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferroptosis: A potential therapeutic target for neurodegenerative diseases.
    Vitalakumar D; Sharma A; Flora SJS
    J Biochem Mol Toxicol; 2021 Aug; 35(8):e22830. PubMed ID: 34047408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases.
    Reichert CO; de Freitas FA; Sampaio-Silva J; Rokita-Rosa L; Barros PL; Levy D; Bydlowski SP
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.